Title : Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.

Pub. Date : 2021

PMID : 34659899






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Asciminib is a novel drug capable of targeting most BCR-ABL1 mutant-forms, including BCR-ABL1T315I, but remains ineffective against most BCR-ABL1T315I+ compound mutation-bearing sub-clones. asciminib BCR activator of RhoGEF and GTPase Homo sapiens